Related Experiment Video
Updated: May 7, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
The Effect of CD31 on Coronary Collateral Development
Huseyin Akcali1, Mustafa Begenc Tascanov1, Kenan Toprak1
1Department of Cardiology, Harran University, Faculty of Medicine, Sanliurfa, Turkiye.
Insights
CD31 levels are higher in patients with coronary artery disease and good coronary collateral development. This suggests CD31, a marker of angiogenesis, may be crucial for coronary collateral growth.
Area of Science:
- Cardiovascular Biology
- Angiogenesis Research
- Medical Diagnostics
Background:
- Coronary collaterals are vital for myocardial function, particularly in coronary artery disease.
- The precise mechanisms driving coronary collateral development remain incompletely understood.
Purpose of the Study:
- To investigate the role of CD31 in the development of coronary collaterals.
- To determine if CD31 levels correlate with coronary artery disease severity and collateralization.
Main Methods:
- Coronary angiography was used to assess collateral development in 89 coronary artery disease patients and 90 controls.
- Serum CD31 levels were measured and compared between groups.
- Subgroup analysis identified factors influencing collateral development.
Main Results:
- CD31 levels were significantly elevated in coronary artery disease patients versus controls (p <0.001).
- Higher CD31 levels correlated with better collateral development (p <0.001).
- CD31 emerged as an independent predictor of good coronary collateralization.
Conclusions:
- CD31, an angiogenesis marker, appears to play a significant role in coronary collateral development.
- Elevated CD31 may indicate enhanced collateral formation in coronary artery disease.
Background:
Coronary collaterals are the feeding bridges between the main epicardial arteries, and research has shown that this collateral development plays a crucial role in myocardial performance, especially in patients with coronary artery disease. However, the evolution of these collaterals has not been fully explained.
Objectives:
In this study, we aimed to reveal the effect of CD31 on coronary collateral development.
Methods:
As a result of coronary angiography performed in our clinic, 89 patients with coronary artery disease and 90 patients with normal coronary arteries were included in the study. Collateral development degrees were recorded from the angiographic images of the subjects. CD31 values were compared between the group with coronary artery disease and the control group. In addition, the coronary artery disease group was divided into subgroups according to the collateral development in terms of good collateral development and poor collateral development, and the factors that may affect the collateral development were tried to be determined.
Results:
CD31 levels were significantly higher in the group with coronary artery disease compared to the control group (p <0.001). In addition, CD31 levels in the subgroup with good collateral were significantly higher than in the group with weak collateral (p <0.001). In the correlation analysis, a significant positive correlation was found between serum CD31 level and SYNTAX score, age, glucose, and rentrop grade. Multivariate logistic regression analysis showed CD31 to be an independent predictor of good coronary collateral development.
Conclusion:
CD31, a marker of angiogenesis, may be involved in coronary collateral development.
